Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and cis-DDP in advanced head and neck cancer: Results and toxicity

Strahlentherapie und Onkologie

Volumn 180, Issue 12, 2004, Pages 805-810

  Ernst Stecken, Antje ^a,c   Grabenbauer, Gerhard ^a   Iro, Heinrich ^a   Plasswilm, Ludwig ^b   Sauer, Rolf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Advanced head and neck cancer; Altered fractionation; Combined modality treatment; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GAMMA IRRADIATION; HEAD AND NECK CANCER; HUMAN; MALE; METASTASIS; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 11944258048     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1307-1     Document Type: Article

References (48)

1. Adelstein DJ, Saxton JP, Lavertu, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002; 20:1405-10.
2. Adelstein DJ, Sharan VM, Earle AS, et al. Simultaneous vs. sequential combined technique therapy for squamous cell head and neck cancer. Cancer 1990;65:1685-91.
3. AlSarraf M, Paja TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 1987;59:259-65.
4. Andreadis C, Vahtsevanos K, Sidiras T, et al. 5-fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol 2003;39:380-5.
5. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 1998;8:230-6.
6. Arcangeli G, Saracino B, Danesi DT, et al. Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer. Am J Clin Oncol 2002;25: 431-7.
7. Bieri S, Bentzen SM, Huguenin P, et al. Early morbidity with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized trials. Strahlenther Onkol 2003;179:390-5.
8. Bourhis J, Pignon JP. Meta-analysis in head and neck squamous cell carcinoma. What is the role of chemotherapy? Hematol Oncol Clin North Am 1999;13:769-75.
9. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
10. Budach VG, Geismar D, Lammert I, et al. Accelerated hyperfractionated radiation therapy to 70.6 Gy plus 5-FU/MMC (C-Hart) is more effective than HART to 77.6 Gy alone for locally advanced head and neck cancer. Four-year results of the German ARO-95-6 trial in 384 patients. Int J Radiat Oncol Biol Phys 2003;57:53-4.
11. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
12. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/ SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003,55:93-8.
13. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Group d'Etudes des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000;83:1594-8.
14. Dunphy F, Boyd J, Varvares M, et al. Phase I trial of preoperative (PRE) chemotherapy using paclitaxel/paraplatin in head and neck carcinoma (HNCA). Proc Am Soc Clin Oncol 1996;16.abstract 892.
15. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
16. Eckardt A, Rades D, Rudat V, et al. Prospective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity. 3-year outcome. Mund Kiefer Gesichtschir 2002;6:117-21.
17. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 1994;21:49-52.
18. Fowler JF, Harari PM. Conformation of improved local-regional control with altered fractionation in head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48:3-6.
19. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
20. Gleich LL, Collins CM, Gartside PS, et al. Therapeutic decision making in stages III and IV in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:26-35.
21. Hall SF, Rochon PA, Streiner DL, et al. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002;112:1988-96.
22. Hathaway B, Johnson JT, Piccirillo JF, et al. Chemoradiation for metastatic SCCA: role of comorbidity. Laryngoscope 2001;111:1893-5.
23. Ho CM, Lam KH, Wei WI, et al. Squamous cell carcinoma of the hypopharynx - analysis of treatment results. Head Neck 1993;15:405-12.
24. Jacobs CM, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
25. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2000;18:1458-64.
26. Kuhnt T, Becker A, Pigorsch S, et al. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 2003;179:673-81.
27. Kumar P, Robbins KT. Treatment of advanced head and neck cancer with intraarterial cisplatin and concurrent radiation therapy: The "RAD-PLAT" protocol. Curr Oncol Rep 2001;3:59-65.
28. Kurek R, Kalogera-Fountzila A, Muskalla K, et al. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol 2003;179:292-7.
29. Laramore GE, Coltrera MD. Organ preservation strategies in the treatment of laryngeal cancer. Curr Treat Options Oncol 2003;4:15-25.
30. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-8.
31. Merlano M, Corvo R, Margarino G, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991;67:915-21.
32. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage II or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e de Collo. J Natl Cancer Inst 1994;86:265-72.
33. Piccirillo JF, Lacy PD, Basu A, et al. Development of a new head and neck cancer specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002; 128:1172-9.
34. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative group meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
35. Saunders MI. Head and neck cancer: altered fractionation schedules. Oncologist 1999;4:11-6.
36. Schafer U, Micke O, Muller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-34.
37. Seegenschmiedt MH. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 1998;174:25-9.
38. Smid L, Lesnicar H, Zakotnik B, et al. Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer - Preliminary report. Int J Radiat Oncol Biol Phys 1995; 32:769-75.
39. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicenter randomised German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71.
40. Stell PM. Adjuvant chemotherapy in head and neck cancer. Semin Radiat Oncol 1992;2:195-205.
41. Studer G, Gratz KW, Glanzmann C. Osteoradionecrosis of the mandibula in patients treated with different fractionations. Strahlenther Onkol 2004; 180:233-40.
42. Tarnawski R, Fowler J, Krzysztof S, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002;54: 229-36.
43. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preservating therapy for advanced head and neck cancer. J Clin Oncol 2003;15:320-26.
44. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia. Predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-11.
45. Wendt TG, Grabenbauer GG, Roedel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-28.
46. Wendt TG. The radiochemotherapy of advanced head-neck cancer tumors - what is certain? Strahlenther Oncol 1996;172:409-16.
47. Zamboglu N, Schnabel T, Kolotas C, et al. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Semin Oncol 1994;21:45-53.
48. Zeng J, Yu QW, Liu WW, et al. Combined use of taxotere in induction chemotherapy of head and neck neoplasms. Ai Zeng 2003;22:877-9.